For columnist Dagmar Munn, reducing uncertainty in one area of her life with ALS would mean keeping her ALS progression right where it is.
Experimental therapy RT1999 will soon be tested in the UK EXPERTS-ALS platform trial designed to rapidly screen potential ALS treatments.
ALS News Today joins the ALS Network’s ASK ME ALS webinar series as presenting sponsor, offering expert discussions on ALS ...
Clinical & Scientific Conference, researchers and clinicians are talking about the central role of patients, families, and caregivers in driving change for people living with neuromuscular diseases.
Chris was diagnosed with ALS in 2024. Before that, he spent 40 years in the oil and gas industry, working and living in eight countries across five continents. He’s dedicated himself to helping others ...
Exposure to wildfire smoke can more than double the risk of respiratory failure or death for ALS patients, a study found.
The president and CEO of the Muscular Dystrophy Association talks about what she's most excited about in neuromuscular ...
Dosing has begun in a new regimen of the HEALEY ALS platform trial, its ninth, which is testing the oral therapy NUZ-001 for ...
Rather than worrying about bucket list adventures, columnist Juliet Taylor and her late husband, Jeff, focused on friends and ...
AB Science says a newly identified blood biomarker may help assess masitinib activity in its ongoing Phase 3 ALS clinical ...
A mutation in the TDP-43 protein reduces the viability of motor neurons without triggering protein clumps, researchers found.
Fat-based vesicles help deliver GM1 to the brain, improving movement and extending survival in mouse models of ALS, a study finds.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results